Core Points - The General Meeting of UCB SA/NV is scheduled for April 30, 2026, to discuss and vote on various agenda items [1] - Shareholders can participate via the Lumi Connect platform for free [2] Ordinary Part - The Board of Directors will present the annual accounts for the financial year ended December 31, 2025, along with the statutory auditor's report [3] - The consolidated annual accounts of the UCB Group for the financial year ended December 31, 2025, will be communicated, including the corporate governance statement and sustainability information [3] - A gross dividend of €1.45 per share is proposed for approval, with the total distribution amount subject to fluctuation based on the number of own shares held by UCB SA/NV [4] - The remuneration report for the financial year ended December 31, 2025, detailing the remuneration policy and information on the Board of Directors and Executive Committee, is also up for approval [5] - Discharge of liability for the directors and the statutory auditor for the financial year ended December 31, 2025, will be voted on [6][8] - The mandates of Mr. Jean-Christophe Tellier and Mr. Cédric van Rijckevorsel are proposed for renewal for four years until the end of the ordinary General Meeting of 2030 [10][11] Special Part - Approval for the renewal of change of control provisions in the EMTN Program is proposed, which allows noteholders to require UCB SA/NV to redeem notes under certain conditions [16][20] - The EMTN Program was established for an amount of €5 billion, with the last update on October 17, 2023 [18] Extraordinary Part - An Extraordinary General Meeting will be convened if the initial meeting does not meet the required quorum, with a new date set for June 2, 2026 [21] - The Board of Directors seeks renewal of its powers under the authorized capital for another two years, allowing capital increases of up to 5% with limitations on preferential subscription rights, or up to 10% without such limitations [24][26] - Authorization for the Board of Directors to acquire up to 10% of the total number of shares for two years starting July 1, 2026, is also proposed [32][34] Participation Formalities - Shareholders must comply with specific formalities to participate in the General Meeting, including registration by April 16, 2026 [38] - Voting by proxy is allowed, and shareholders must submit their proxy forms by April 24, 2026 [44][46]

Core Viewpoint - Pharming Group N.V. has received a positive opinion from the CHMP of the EMA recommending marketing authorization for Joenja® (leniolisib) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 years and older, marking a significant advancement in APDS care in Europe [1][3][6]. Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for rare and life-threatening diseases, headquartered in Leiden, the Netherlands [10]. Product Information - Joenja® (leniolisib) is an oral small molecule PI3Kδ inhibitor, currently approved in the U.S., U.K., Australia, and Israel for patients aged 12 years and older with APDS, and in Japan for patients aged 4 years and older [8][4]. - The positive CHMP opinion is based on a Phase II/III clinical trial involving 31 patients, demonstrating a statistically significant impact on immune dysregulation and immunodeficiency [3][6]. Market Potential - If approved by the European Commission, Joenja would be the first treatment for APDS in the European Union, with centralized marketing authorization valid across all 27 EU Member States, Norway, Iceland, and Liechtenstein [2][6]. Clinical Insights - The clinical program for leniolisib has shown meaningful improvements in immune dysregulation and deficiency, suggesting it could significantly change the clinical outlook for patients with APDS [4][3]. - APDS affects approximately 1 to 2 individuals per million worldwide, and patients often experience a median diagnostic delay of 7 years [7][5].

Core Insights - The establishment of a 950MW Concentrated Solar Power and Photovoltaic (CSP-PV) plant in Dubai marks a significant milestone in China-UAE green cooperation, being the world's largest single-site CSP-PV project [1][2] Financing and Collaboration - Agricultural Bank of China (ABC) has developed an innovative financing model to address challenges in green energy projects, enabling the syndication of USD 2.5 billion loans to facilitate international cooperation on production capacity [2] - ABC's Dubai International Financial Centre (DIFC) Branch plays a crucial role in organizing international lenders to partner with EPC contractors, thus breaking financing bottlenecks [2] Project Impact - The CSP-PV plant will provide clean electricity to over 320,000 households in Dubai, reducing CO2 emissions by more than 1.6 million tonnes annually, and is integral to the UAE's Net Zero 2050 strategy [7] - The project is expected to create approximately 4,000 direct jobs and over 10,000 indirect jobs during its construction and operation [7] Implementation and Challenges - Key challenges include high leverage with low equity contribution, sub-optimal risk allocation, and the need for timely fund disbursement due to construction uncertainties [5] - ABC has optimized the financing structure by introducing a "cash sweep mechanism" and synchronizing fund disbursement with the project timeline, while also establishing emergency response mechanisms [6] Demonstration Value - The project serves as a model for integrating finance and industry to support cross-border green energy initiatives, showcasing the effectiveness of China's green finance solutions in promoting global sustainable development [8]

Core Insights - The Lynx M20 wheeled-legged robot by DEEP Robotics has won the prestigious 2026 German iF Design Award, highlighting its innovative design and technological advancements [1][2][11] Design Innovation - The Lynx M20 follows the design philosophy of "form follows function," optimizing its architecture for practical use while maintaining aesthetic appeal [3] - It features a symmetrical design that allows for flexible navigation in tight spaces and supports rapid deployment with customizable payload configurations [3] - The robot's modular design includes interchangeable limbs for improved maintenance efficiency and reduced costs [3] - The "wheel-legged hybrid" structure combines the speed of wheeled mobility with the adaptability of legged locomotion, enhancing operational efficiency in complex scenarios [3] Functional Capabilities - The Lynx M20 is designed for extreme environments, with all-weather protection and a wide operating temperature range of -20°C to 55°C, ensuring stable performance in harsh conditions [5] - It has an IP66 protection rating, making it resilient against sandstorms, rain, snow, and dust, thus suitable for hazardous outdoor inspections [5] - The robot features a hot-swappable battery design for uninterrupted operation, enhancing work efficiency [5] Scenario Deployment - The Lynx M20 has been deployed in various applications, including power inspections, security patrols, and emergency firefighting, addressing operational challenges in extreme environments [8][9] - In power inspection, it improves efficiency and safety by replacing manual inspections, which are often time-consuming and risky [9] - The robot has been utilized in innovative scenarios, such as broadcasting sports events and transporting supplies in high-altitude areas, showcasing its versatility [10] Market Position - DEEP Robotics has established itself as a leader in the quadruped robot market, ranking first globally in market share for quadruped robot applications as of 2025 [14] - The company has expanded its operations to 50 countries and regions, with over 1,200 successful deployments in various industry scenarios [14]

Core Insights - Icelandic Salmon AS has published its integrated Annual Report for 2025, which includes sustainability reporting and complete annual accounts with notes [1] - The company is dual-listed on the Euronext Growth in Oslo and NASDAQ First North in Reykjavík [1] - Icelandic Salmon is the 100% owner of Arnarlax ehf, a farming company in Iceland, and is fully integrated from egg to fish delivery [1] Company Overview - Icelandic Salmon AS operates with its head office located in Bíldudalur, Iceland [1] - The Group maintains control over all parts of the value chain, ensuring quality and efficiency in its operations [1] Reporting and Compliance - The Annual Report is available on the company's investor website [2] - The information is subject to the disclosure requirements of the Norwegian Securities Trading Act [2]

Core Viewpoint - Zenas BioPharma, a clinical-stage biopharmaceutical company, has announced the pricing of a $200 million public offering of convertible senior notes and a $100 million equity offering, aiming to raise approximately $287.5 million in net proceeds to support its product development and commercialization efforts [1][2]. Group 1: Offerings Details - The company is offering $200 million in 2.50% convertible senior notes due 2032 and 5 million shares of common stock at $20.00 per share [1]. - The net proceeds from both offerings are estimated to be around $287.5 million after deducting underwriting discounts and expenses [2]. - The offerings are expected to close on March 31, 2026, subject to customary closing conditions [3]. Group 2: Convertible Notes Characteristics - The convertible notes will be unsecured senior obligations, accruing interest at 2.50% per year, with a maturity date of April 1, 2032 [4]. - Noteholders can convert their notes under certain conditions, with an initial conversion rate of 37.7358 shares per $1,000 principal amount, equating to a conversion price of approximately $26.50 per share [5]. - The notes are redeemable at the company's option after April 8, 2030, under specific conditions related to the stock price [6]. Group 3: Use of Proceeds - The company intends to use the proceeds to support the U.S. commercial launch of obexelimab for IgG4-RD treatment, advance its development pipeline, and for general corporate purposes [8]. Group 4: Company Overview - Zenas BioPharma focuses on developing transformative therapies for autoimmune diseases, with key products including obexelimab and orelabrutinib [13]. - Obexelimab is designed to inhibit pathogenic B cells without depleting them, while orelabrutinib targets B cells in both peripheral and central nervous systems [13].

Core Viewpoint - Colabor Group Inc. is progressing with its sale and investment solicitation process under court supervision, having accepted four binding offers for its assets and operations, with definitive agreements for three transactions being finalized [2][3]. Group 1: Sale and Investment Solicitation Process - The company is under restructuring proceedings initiated on January 8, 2026, under the Companies' Creditors Arrangement Act (Canada) [1]. - Four binding offers have been accepted for the substantial totality of Colabor's assets and operations, with three definitive agreements currently being finalized [2]. - A finalized share purchase agreement has been made with a newly incorporated corporation for the purchase of all outstanding shares of Tout-Prêt Inc. on behalf of existing employees [2]. Group 2: Court Proceedings and Approvals - Colabor has applied to the court for an approval and vesting order regarding the share purchase agreement, with a hearing scheduled for March 31, 2026 [3]. - The company plans to seek approval for the other three transactions in the coming weeks and has filed for a stay of proceedings until May 1, 2026, to be heard during the upcoming hearing [4]. Group 3: Company Overview - Colabor is a distributor and wholesaler of food and related products, serving the hotel, restaurant, and institutional markets in Quebec and the Atlantic provinces, as well as the retail market [5].

Core Viewpoint - Novo Nordisk has received FDA approval for Awiqli, the first and only once-weekly long-acting basal insulin for adults with type 2 diabetes, providing a new treatment option that aligns with patient preferences and routines [1][3]. Group 1: Product Details - Awiqli (insulin icodec-abae) is approved at a concentration of 700 units/mL and is indicated as an adjunct to diet and exercise for improving glycaemic control in adults with type 2 diabetes [1][5]. - The approval is based on the ONWARDS phase 3a clinical program, which included approximately 2,680 adults with uncontrolled type 2 diabetes, demonstrating efficacy in reducing HbA1c levels compared to daily basal insulin [2][5]. - Awiqli is designed to be administered once weekly using the Awiqli FlexTouch device, reducing the frequency of injections from seven to one per week [8]. Group 2: Market and Launch Information - Novo Nordisk plans to launch Awiqli in the US in the second half of 2026, and it is already approved in the EU and 13 additional countries [4][8]. - The company emphasizes its commitment to innovation in diabetes care, especially at a time when some industry players are reducing their focus on insulin products [3]. Group 3: Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923, headquartered in Denmark, and employs approximately 68,800 people across 80 countries [6]. - The company markets its products in around 170 countries and is listed on Nasdaq Copenhagen and the New York Stock Exchange [6].

Core Viewpoint - Vemanti Group, Inc. is currently facing an investigation in Vietnam related to its ONUS Pro cryptocurrency platform, following the indictments of key board members [1][2]. Group 1: Company Situation - The Company has learned about the indictments of Chairman Nhan ("Eric") Vuong and board member Chien Tran through an official announcement from Vietnam's Ministry of Public Security [2]. - Prior to the announcement, the Company had not received any official communication from authorities regarding the matter [2]. - The Company's Board of Directors is actively monitoring the situation and has engaged legal counsel in the United States to assess the implications and determine the appropriate course of action [3]. Group 2: Company Overview - Vemanti Group, Inc. is a diversified technology holding company focused on emerging markets in Southeast Asia, operating in various sectors of digital financial services [4]. - The Company aims for growth through strategic partnerships, joint ventures, and mergers and acquisitions, leveraging synergies to expand market reach and create long-term shareholder value [4].

Core Points - Itafos Inc. has granted a total of 477,535 restricted share units (RSUs) and 32,738 deferred share units (DSUs) to its directors and officers, with RSUs vesting one-third per annum over three years [1][2] - The RSUs for officers are structured with 50% vesting annually over three years and the remaining 50% vesting on the third anniversary, contingent on achieving specific key performance indicators [2] - Each vested RSU allows the holder to receive one share of common stock or a cash equivalent, while vested DSUs provide a cash payment equal to the fair market value of one share upon cessation of service [3][4] Company Overview - Itafos is a phosphate and specialty fertilizer company operating across three continents, with its shares traded on TSX-V under the ticker "IFOS" and on OTCQX under "ITFS" [5] - The principal shareholder of Itafos is CLF, an affiliate of Castlelake, L.P., a global private investment firm [5] - The company has various operations, including a vertically integrated phosphate fertilizer business in Idaho, production targets in Brazil, and high-grade phosphate mine projects in Guinea-Bissau and Brazil [7]